Subcutaneous (SC) administration

Subcutaneous (SC) administration involves injecting a solution into the loose connective tissue and fat layer that sits just beneath the dermis and above the muscle fascia. Absorption from the subcutaneous space is slower and more sustained than intramuscular (IM) injection because the subcutaneous fat layer is less vascularised, allowing the injected fluid to be absorbed gradually via capillaries and lymphatics. This absorption profile is often advantageous for peptides where a sustained release rather than a rapid peak is desired.

Why it matters in peptide research

Subcutaneous injection is the default route in the vast majority of research peptide protocols for several reasons. First, it is technically simpler and carries lower risk of injury than intramuscular injection — the target tissue is superficial and easily accessible at multiple sites (abdomen, thigh, upper arm). Second, the slower absorption from the SC depot reduces the height and sharpens the fall of the plasma concentration curve relative to IV administration, which is more compatible with peptides that require a pulse-like pharmacokinetic profile. Third, most of the pharmacokinetic data for research peptides in animal and human studies are derived from SC administration, making SC the most evidence-matched route.

For SC injection, standard practice in research protocols uses insulin syringes — typically 29–31 gauge, 6–8 mm needle length — because the small needle minimises discomfort and the syringe's graduation in insulin units (IU) requires the researcher to correctly convert peptide concentration to volume. At a standard concentration of 1 mg/mL (1000 mcg per mL), 100 IU on an insulin syringe equals 0.1 mL, delivering 100 mcg of peptide. Correctly mapping dose (in mcg) to volume (in mL) and then to insulin units is one of the most error-prone steps in peptide protocols and should always be double-checked using a reconstitution calculator.

Common SC injection sites are the lower abdomen (avoiding the 2 cm zone around the navel), the lateral thigh, and the posterior upper arm. Sites should be rotated to prevent lipohypertrophy — fatty lumps from repeated injection at the same point that slow and inconsistently modify absorption.

Peptides / stacks that act on this

Subcutaneous injection is the standard administration route documented for BPC-157, TB-500, CJC-1295, Ipamorelin, GHK-Cu, Epitalon, Tesamorelin, and most other peptides profiled on this site.

Reading tip

"Units" on an insulin syringe refer to insulin units, not micrograms. The IU graduation system assumes a concentration of 100 IU/mL for standard U-100 insulin. When using insulin syringes to administer research peptides at a known mg/mL concentration, calculate the required volume in mL first and then determine the corresponding syringe graduation — never assume "units" equals micrograms.